IMMUNIC INC (IMUX) Stock Price, Quote, News and Overview
NASDAQ:IMUX - Nasdaq - US4525EP1011 - Common Stock - Currency: USD
IMUX Quote, Performance and Key Statistics
1.27
+0.09 (+7.63%)
The current stock price of IMUX is 1.27 USD. In the past month the price increased by 27.95%. In the past year, price increased by 4.1%.
IMUX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IMUX
Company Profile
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 77 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Company Info
IMMUNIC INC
1200 Avenue Of The Americas, Suite 200
New York City NEW YORK 10036 US
CEO: Daniel Vitt
Employees: 85
Company Website: https://imux.com/
Investor Relations: https://ir.imux.com
Phone: 13322559818
IMMUNIC INC / IMUX FAQ
What is the stock price of IMMUNIC INC today?
The current stock price of IMUX is 1.27 USD. The price increased by 7.63% in the last trading session.
What is the ticker symbol for IMMUNIC INC stock?
The exchange symbol of IMMUNIC INC is IMUX and it is listed on the Nasdaq exchange.
On which exchange is IMUX stock listed?
IMUX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNIC INC stock?
12 analysts have analysed IMUX and the average price target is 13.43 USD. This implies a price increase of 957.48% is expected in the next year compared to the current price of 1.27. Check the IMMUNIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNIC INC worth?
IMMUNIC INC (IMUX) has a market capitalization of 114.40M USD. This makes IMUX a Micro Cap stock.
How many employees does IMMUNIC INC have?
IMMUNIC INC (IMUX) currently has 85 employees.
What are the support and resistance levels for IMMUNIC INC (IMUX) stock?
IMMUNIC INC (IMUX) has a support level at 0.95 and a resistance level at 1.28. Check the full technical report for a detailed analysis of IMUX support and resistance levels.
Should I buy IMMUNIC INC (IMUX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMUX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMUX, evaluating the profitability, health, valuation and growth aspects
- IMMUNIC INC (IMUX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNIC INC (IMUX) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNIC INC (IMUX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNIC INC (IMUX) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNIC INC (IMUX) Stock Chart to make your own analysis
- IMMUNIC INC (IMUX) Latest news and press-releases to stay up to date.
Does IMMUNIC INC (IMUX) stock pay dividends?
IMUX does not pay a dividend.
When does IMMUNIC INC (IMUX) report earnings?
IMMUNIC INC (IMUX) will report earnings on 2025-05-06, before the market open.
What is the Price/Earnings (PE) ratio of IMMUNIC INC (IMUX)?
IMMUNIC INC (IMUX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.23).
What is the Short Interest ratio of IMMUNIC INC (IMUX) stock?
The outstanding short interest for IMMUNIC INC (IMUX) is 4.21% of its float. Check the ownership tab for more information on the IMUX short interest.
IMUX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IMUX. When comparing the yearly performance of all stocks, IMUX is one of the better performing stocks in the market, outperforming 76.06% of all stocks.
IMUX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMUX. The financial health of IMUX is average, but there are quite some concerns on its profitability.
IMUX Financial Highlights
Over the last trailing twelve months IMUX reported a non-GAAP Earnings per Share(EPS) of -1.23. The EPS increased by 62.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -149.63% | ||
| ROE | -235.1% | ||
| Debt/Equity | 0 |
IMUX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to IMUX. The Buy consensus is the average rating of analysts ratings from 12 analysts.